Protein biomarker detection platform Alamar Biosciences files for a $100 million IPO
IPO Overview
Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company develops and commercializes proteomics technologies designed to detect and analyze protein biomarkers at very low concentrations in biological samples such as blood. Its platform combines proprietary instruments, consumables, and software to provide an end-to-end system for measuring multiple low-abundance proteins across research and potential clinical applications. The company’s technology is used in areas ranging from early-stage discovery to translational research, with an emphasis on enabling more precise and consistent protein detection.
The Fremont, CA-based company was founded in 2018 and booked $74 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol ALMR. Alamar Biosciences filed confidentially on January 9, 2026. J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel are the joint bookrunners on the deal.
About the Company
Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput （“HT”） System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch.
